Continuous vs. single-shot adductor canal block for pain management following primary total knee arthroplasty: A systematic review and meta-analysis of randomized controlled trials

Adductor canal block (ACB) provides effective analgesia following total knee arthroplasty (TKA). This systematic review aimed to compare continuous and single-shot ACB for pain management and functional recovery following TKA. MEDLINE, Embase, Web of Science and CENTRAL were searched up to January 5...

Full description

Saved in:
Bibliographic Details
Published in:Orthopaedics & traumatology, surgery & research surgery & research, 2022-12, Vol.108 (8), p.103290-103290, Article 103290
Main Authors: Sercia, Quentin P., Bergeron, Jérémy J., Pelet, Stéphane, Belzile, Étienne L.
Format: Article
Language:English
Subjects:
Adductor canal block
Analgesics, Opioid - therapeutic use
Arthroplasty, Replacement, Knee - adverse effects
Arthroplasty, Replacement, Knee - methods
Femoral Nerve
Functional recovery
Humans
Nerve Block - methods
Opioid consumption
Pain management
Pain Management - methods
Pain, Postoperative - prevention & control
Randomized Controlled Trials as Topic
Total knee arthroplasty
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adductor canal block (ACB) provides effective analgesia following total knee arthroplasty (TKA). This systematic review aimed to compare continuous and single-shot ACB for pain management and functional recovery following TKA. MEDLINE, Embase, Web of Science and CENTRAL were searched up to January 5th, 2021. Included studies were randomized controlled trials comparing continuous to single-shot ACB for postoperative pain management after primary TKA. Primary outcome was opioid consumption and secondary outcomes were pain intensity, quadriceps strength, mobility, complications, and length of hospital stay. Meta-analyses were performed using random-effects method. Eleven studies (910 patients) were included in this systematic review. Continuous ACB did not significantly decrease opioid consumption (8 studies; 642 patients; MD=−5.67; 95% CI: −13.87 to 2.54; I2=13%) but significantly decreased 48hours pain scores (10 studies; 852 patients; MD=−0,73; 95% CI: −0.93 to −0.54; I2=54%). Continuous ACB improved quadriceps strength (4 studies; 250 patients; SMD=0.59; 95% CI: 0.16 to 1.03; I2=63%) but not Timed Up and Go test performance (5 studies; 524 patients; MD=3.99; 95% CI: −8.98 to 1.01; I2=89%). Type of ACB did not affect nausea and vomiting (5 studies; 357 patients; RR=1.23; 95% CI: 0.65 to 2.34; I2=0%) nor length of hospital stay (8 studies; 655 patients; MD=−0.13; 95% CI: −0.28 to 0.01; I2=36%). Continuous ACB did not reduce opioid consumption following TKA. Larger trials are required.
ISSN:1877-0568
1877-0568
DOI:10.1016/j.otsr.2022.103290